Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
January 2017
-
Media ReleaseNovartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disordersNovartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
-
A New Year’s resolution for COPD
Discover how COPD assessment and treatment are changing.
December 2016
-
Media ReleaseNovartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients…
-
Media ReleaseNovartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseasesNovartis to broaden liver portfolio to deliver best-in-class single and combination therapies for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis through an option,…
-
Media ReleaseNovartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever SyndromesPeriodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
-
Media ReleaseNovartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSCIf approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
-
Media ReleaseNovartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group LimitedAcquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational…
-
In The NewsConfronting the next global health challengeNovartis Chairman Joerg Reinhardt says the successful fight against infectious diseases in poor countries provides valuable lessons for the emerging crisis of chronic diseases.
-
Media ReleaseNovartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicinesSMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
-
Media ReleaseNovartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentielsSMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce…
-
Media ReleaseNovartis führt "SMS for Life 2.0" in Nigeria ein, um den Zugang zu unentbehrlichen Arzneimitteln zu verbessern"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
-
Media ReleaseNovartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
Pagination
- ‹ Previous page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- …
- 152
- › Next page